(813) 971-8080

7210 Wareham Drive, Tampa, FL 33647

Author name: John LaRosa

$38.4 Billion U.S. Commercial Weight Loss Market Pivots To Survive GLP-1 Drugs Explosion

News /

March 24, 2025 Marketdata LLC has just published a new report: “The U.S. Weight Loss Market: Commercial (non-medical) Programs & Products”, March 2025. This is a 220-page analysis of commercial weight loss programs/companies and how they have been affected by and respond to the onslaught of the GLP-1 drugs competition. The $38 billion U.S. commercial weight loss […]

$38.4 Billion U.S. Commercial Weight Loss Market Pivots To Survive GLP-1 Drugs Explosion Read More »

FDA Says No More Compounded Weight Loss Drugs – Industry OFA Appeal Shot Down

News /

March 14, 2025 On Mar. 5, a judge denied a request from the Outsourcing Facilities Association (OFA), an industry group for compounding pharmacies, to block the FDA’s attempt to stop the production of compounded tirzepatide. Generally, making copies of brand-name drugs is not legal until their patents expire. But there are exceptions: Compounding pharmacies can

FDA Says No More Compounded Weight Loss Drugs – Industry OFA Appeal Shot Down Read More »

Recession Is Coming – But Commercial Diet Companies Could Benefit

News /

March 13, 2025 Marketdata, the parent company of DietBusinessWatch.com, is currently updating its report on the Commercial & Retail Weight Loss Market. Several things have become apparent as we do the research Marketdata analysts see a possible opportunity this year for the commercial (non-medical) weight loss firms to recover some ground. Here’s how we think

Recession Is Coming – But Commercial Diet Companies Could Benefit Read More »

$33 Billion U.S. Medical Weight Loss Market Dominated by GLP-1 Drugs – New Report

News /

Feb. 27, 2025 Marketdata LLC has published anew 154-page analysis of the U.S. weight loss market, entitled: “The U.S. Medical Weight Loss Market: The Impact of GLP-1 Drugs on Doctors, Hospitals, Clinics and Franchises”, February 2025. This report presents a complete picture of the medical weight loss market in the United States, with the inter-relationships between competing

$33 Billion U.S. Medical Weight Loss Market Dominated by GLP-1 Drugs – New Report Read More »

Herbalife Reports 2024 Results, $567 Million Weight Loss U.S. Sales

News /

Feb. 2o, 2025 Herbalife reported Q4 and full year 2024 results. The company sells a significant amount of weight loss and meal replacement products each year. “With three consecutive quarters of new distributor growth, a new incoming CEO and significantly improved Adjusted EBITDA2 margins, we enter 2025 with strong momentum.” – Michael Johnson, Chairman and

Herbalife Reports 2024 Results, $567 Million Weight Loss U.S. Sales Read More »

Copyright © 2024 Diet Busine$$ Watch. All rights reserved. | Login | website developed by CP Communications

 

Scroll to Top